These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24529291)

  • 1. Challenges for academic investigator-initiated pediatric trials for rare diseases.
    Ahmed R; Duerr U; Gavenis K; Hilgers R; Gross O
    Clin Ther; 2014 Feb; 36(2):184-90. PubMed ID: 24529291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.
    Gross O; Beirowski B; Koepke ML; Kuck J; Reiner M; Addicks K; Smyth N; Schulze-Lohoff E; Weber M
    Kidney Int; 2003 Feb; 63(2):438-46. PubMed ID: 12631109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients.
    Gross O; Friede T; Hilgers R; Görlitz A; Gavénis K; Ahmed R; Dürr U
    ISRN Pediatr; 2012; 2012():436046. PubMed ID: 22811928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?
    Rheault MN; Smoyer WE
    Kidney Int; 2020 Jun; 97(6):1104-1106. PubMed ID: 32444091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.
    Gross O; Licht C; Anders HJ; Hoppe B; Beck B; Tönshoff B; Höcker B; Wygoda S; Ehrich JH; Pape L; Konrad M; Rascher W; Dötsch J; Müller-Wiefel DE; Hoyer P; ; Knebelmann B; Pirson Y; Grunfeld JP; Niaudet P; Cochat P; Heidet L; Lebbah S; Torra R; Friede T; Lange K; Müller GA; Weber M
    Kidney Int; 2012 Mar; 81(5):494-501. PubMed ID: 22166847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
    Georgias C; Grunow A; Olderog M; May A; Paulus U
    Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome.
    Gross O; Tönshoff B; Weber LT; Pape L; Latta K; Fehrenbach H; Lange-Sperandio B; Zappel H; Hoyer P; Staude H; König S; John U; Gellermann J; Hoppe B; Galiano M; Hoecker B; Ehren R; Lerch C; Kashtan CE; Harden M; Boeckhaus J; Friede T;
    Kidney Int; 2020 Jun; 97(6):1275-1286. PubMed ID: 32299679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Alport syndrome: beyond animal models.
    Gross O; Kashtan CE
    Kidney Int; 2009 Sep; 76(6):599-603. PubMed ID: 19536083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.
    Seeman T; Dusek J; Vondrák K; Flögelová H; Geier P; Janda J
    Am J Hypertens; 2004 May; 17(5 Pt 1):415-20. PubMed ID: 15110900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.
    Webb NJ; Lam C; Shahinfar S; Strehlau J; Wells TG; Gleim GW; Le Bailly De Tilleghem C
    Nephrol Dial Transplant; 2011 Aug; 26(8):2521-6. PubMed ID: 21285125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation--study design.
    Knoll GA; Cantarovitch M; Cole E; Gill J; Gourishankar S; Holland D; Kiberd B; Muirhead N; Prasad R; Tibbles LA; Treleaven D; Fergusson D
    Nephrol Dial Transplant; 2008 Jan; 23(1):354-8. PubMed ID: 17848393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
    Jaillon P
    Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
    Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs controlling proteinuria of patients with Alport syndrome.
    Li JG; Ding J; Wang F; Zhang HW
    World J Pediatr; 2009 Nov; 5(4):308-11. PubMed ID: 19911149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.